WallStSmart

Abbott Laboratories (ABT)vsKoninklijke Philips NV ADR (PHG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 153% more annual revenue ($45.13B vs $17.83B). ABT leads profitability with a 13.9% profit margin vs 5.0%. PHG appears more attractively valued with a PEG of 0.32. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 5.3Quality: 4.8
Piotroski: 3/9

PHG

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 5.0Value: 7.3Quality: 5.3
Piotroski: 6/9Altman Z: 1.47
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTFair Value (-0.1%)

Margin of Safety

-0.1%

Fair Value

$87.50

Current Price

$89.46

$1.96 premium

UndervaluedFair: $87.50Overvalued
PHGUndervalued (+3.8%)

Margin of Safety

+3.8%

Fair Value

$33.33

Current Price

$26.16

$7.17 discount

UndervaluedFair: $33.33Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$155.82B9/10

Large-cap with strong market position

Price/BookValuation
3.0x8/10

Reasonable price relative to book value

PHG3 strengths · Avg: 8.7/10
PEG RatioValuation
0.3210/10

Growing faster than its price suggests

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$1.31B8/10

Generating 1.3B in free cash flow

Areas to Watch

ABT3 concerns · Avg: 3.0/10
P/E RatioValuation
25.1x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

PHG4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.1%4/10

1.1% revenue growth

Return on EquityProfitability
7.8%3/10

ROE of 7.8% — below average capital efficiency

Profit MarginProfitability
5.0%3/10

5.0% margin — thin

EPS GrowthGrowth
-0.5%2/10

Earnings declined 0.5%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.33 suggests the stock is reasonably priced for its growth.

Bull Case : PHG

The strongest argument for PHG centers on PEG Ratio, Price/Book, Free Cash Flow. PEG of 0.32 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are P/E Ratio, Piotroski F-Score, EPS Growth.

Bear Case : PHG

The primary concerns for PHG are Revenue Growth, Return on Equity, Profit Margin.

Key Dynamics to Monitor

PHG carries more volatility with a beta of 0.92 — expect wider price swings.

ABT is growing revenue faster at 7.8% — sustainability is the question.

PHG generates stronger free cash flow (1.3B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABT scores higher overall (56/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Koninklijke Philips NV ADR

HEALTHCARE · MEDICAL DEVICES · USA

Koninklijke Philips NV is a healthcare technology company in North America, Greater China and internationally. The company is headquartered in Amsterdam, the Netherlands.

Want to dig deeper into these stocks?